Clinical trial · Observational
RWS of Inetetamab HER2 Positive Advanced Breast Cancer
Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer
NCT04963608CI-TRIAL-00052707unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2-positive Advanced Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Inetetamab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- non-interventional study
- description
- Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
- interventionNames
- Drug: Inetetamab
Primary outcomes (2)
- measure
- Progression Free Survival(PFS)
- timeFrame
- 12 months
- measure
- Incidences of adverse events and toxicities
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with stage IV breast cancer 2. Patients with HER2 positive status 3. Patients that received Inetetamab 4. Patients that began Inetetamab therapy prior to June 30, 2021. Exclusion Criteria: Patients treated with an investigational anticancer agent Inetetamab
References
Publications (0)
Data not yet available
No reference posted for this study.